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Diego, CA) for association with treatment-related outcomes in the INternational VErapamil SR -Trandolapril STudy (INVEST), a hypertension outcomes trial. 5 In addition, we replicated our fi ndings in the NORdic DILtiazem (NORDIL) study, another hypertension outcomes trial with similar treatment regimens. 6 
Methods

Study Participants
The INVEST-GENEtic Substudy (INVEST GENES) collected DNA from 5979 patients with hypertension and coronary artery disease enrolled in INVEST, residing in the United States and Puerto Rico. The genetic substudy was approved by the Institutional Review Board at the University of Florida; all patients provided voluntary, written informed consent, and all study procedures were in accordance with institutional guidelines and adhered to the principles of the Declaration of Helsinki and the US Code of Federal Regulations for Protection of Human Subjects. The methods and results of INVEST have been previously published. 5 Briefl y, patients were randomized to a verapamil-SR (CCB) or an atenolol ( β B)-based treatment strategy, with hydrochlorothiazide and trandolapril available as add-on treatment for BP control. The primary outcome (PO) was the fi rst occurrence of all-cause death, nonfatal MI, or nonfatal stroke. Secondary outcomes included the individual components of the PO. Overall, BP control and cardiovascular outcomes were similar between the 2 strategies. 5 A nested case -control cohort was constructed from INVEST-GENES. Cases (n=269) were defi ned as those patients experiencing the PO. Each case was frequency matched to 4 controls (n=1076) based on age by decade, sex, and race/ethnicity. Patients in the casecontrol cohort were primarily classifi ed as white (n=795), Hispanic (n=380), and black (n=170). The results presented here were limited to the white and Hispanic race/ethnic groups because there is limited power in the black race/ethnic group.
DNA was collected on 4200 Swedish subjects from NORDIL, a hypertension outcomes trial comparing a CCB strategy (diltiazem) to conventional antihypertensive treatment using diuretics, β Bs, or both. The primary end point was fatal or nonfatal stroke, fatal or nonfatal MI, or other cardiovascular death, and information is available on all death events. The methods and results of NORDIL have been previously published. 6 Additional details on the study designs and participants for INVEST and NORDIL are available in the online-only Data Supplement.
Genotyping and Quality Control
All 1345 INVEST patients in the nested case -control cohort were successfully genotyped on the Illumina HumanCVD Beadchip, a gene-centric array containing ≈ 50 000 SNPs in ≈ 2100 genes involved in cardiovascular, infl ammatory, and metabolic processes. 4 Four thousand one hundred ninety-six NORDIL subjects were successfully genotyped on the Illumina 610Quad genome-wide array (Illumina). Additional genotyping and quality control details are available in the online-only Data Supplement.
Statistical Analysis
This analysis was limited to nsSNPs on the HumanCVD Beadchip, with a minor allele frequency ≥ 0.03, to identify markers with the greatest likelihood for functional effect and the greatest potential to replicate across race/ethnic groups in INVEST. Genome-spanning nsSNP × treatment interaction analyses were conducted by race/ ethnic group under an additive genetic model using PLINK ( http:// pngu.mgh.harvard.edu/purcell/plink/ ). 7 Analyses were adjusted for age, sex, principal components for ancestry, and history of MI, heart failure, and diabetes mellitus. The primary inference was made from the SNP × treatment interaction analysis in whites. The screening threshold was set at interaction P < 0.05 in whites based on the a priori hypothesis that nsSNPs are likely to be functional. SNPs meeting the screening P value were examined in Hispanics for evidence of association. The signifi cance threshold to move forward to our external replication cohort was P < 0.05, with consistent direction of association. Thus, signifi cant hits had a P < 0.00125 (0.05 × 0.05 × 0.5). Gene regions were also examined because patterns of linkage disequilibrium may vary between race/ethnic groups. For SNPs that showed consistent evidence of a pharmacogenomic (treatment interaction) association in both race/ethnic groups, whites and Hispanics were pooled together and a combined treatment interaction analysis was conducted. Adjusted odds ratios (OR) and 95% confi dence intervals (CIs) for the occurrence of the PO were assessed by genotype using a logistic regression model, under both additive and dominant genetic models of inheritance, using SAS version 9.2 (Cary, NC). Pairwise measure of r 2 and D ′ of top hits were assessed using Haploview version 4.2. 8 Based on the initial fi ndings in the 3 groups (INVEST whites, INVEST Hispanics, and NORDIL), the fi nal genetic risk score was calculated from rs16982743, rs893184, and rs4525. One point was given for each genotype that conferred higher risk in the CCB arm/ group versus the β B arm/group. The potential genetic risk scores ranged from 0 to 3 (1 point each for SIGLEC12 rs16982743 GG [Gln/Gln], A1BG rs893184 GG [Arg/Arg], and F5 rs4525 AA [His/ His]). The risk scores were dichotomized as low risk (0 -1 points) and high risk (2 -3 points) because only a small number of subjects had a score of 0 and 3, and they responded similarly to those with a score of 1 and 2, respectively. Adjusted ORs and 95% CIs for the occurrence of the PO were assessed by genetic risk score using a logistic regression model in SAS version 9.2 (Cary, NC). Secondary outcomes were also tested in INVEST with the fi nal risk score. The signifi cance level for the fi nal risk score × treatment interaction in INVEST whites and Hispanics was P < 0.05, and the signifi cance level in NORDIL was a 1-sided P < 0.05 because we had a 1-sided hypothesis for replication. Meta-analysis for the risk score was conducted using METAL and PLINK. 7 , 9 A weighted model was also tested but discarded because it was more complex but not more informative. Additional details of the statistical methods are available in the online-only Data Supplement.
Results
Study Population and Baseline Characteristics
Baseline demographics and characteristics of the INVEST-GENES case -control cohort and NORDIL subjects are shown in Table 1 . On average, INVEST subjects were older than NORDIL subjects. In addition, INVEST subjects had lower systolic BP and diastolic BP, but this is likely explained by the fact that there was no washout of antihypertensive drugs in INVEST and 87.6% of INVEST subjects were treated at entry, whereas there was a washout in NORDIL ( Table 1 ) . Furthermore, the baseline demographics and characteristics of the INVEST-GENES case -control cohort and NORDIL subjects stratifi ed by treatment group are shown in Table S1 in the online-only Data Supplement.
Genome-Spanning Interaction Analysis and Between-Race Consistency in INVEST
After SNP quality control procedures and applying a minor allele frequency cutoff of ≥ 0.03, there were 1313 nsSNPs analyzed in the white race/ethnic group in INVEST. Sixtyfi ve nsSNPs in the white race/ethnic group had a treatment interaction P < 0.05. Two nsSNPs from whites showed evidence of consistent association in Hispanics: additive P < 0.05 and consistent direction of association ( Table 2 ; Figure S1 ). Allele counts and Hardy-Weinberg Equilibrium data are shown in Table S2 .
The fi rst SNP, rs16982743 in SIGLEC12 (sialic acidbinding Ig-like lectin 12), results in a stop codon at amino acid position 29 (white interaction P =0.0329, Hispanic interaction P =0.0215, and combined interaction P =0.0038; Table 2 ; Figure S1A ). In whites at rs16982743, stop codon carriers (A carriers) showed similar risk for the PO when treated with the CCB versus β B strategy (OR [95% CI]=0.78 [0.43 -1.40]; P =0.4015), whereas in those subjects with the Gln/Gln (G/G) genotype, the risk for the PO was higher in the CCB strategy compared with the β B strategy (OR [95% CI]=1.94 [1.21 -3.14]; P =0.0065; interaction P =0.0159). There was a consistent association in Hispanics, so the white and Hispanic groups were pooled for a combined analysis. OR (95% CI) for stop codon carriers and Gln/ Gln subjects were 0.82 (0.51 -1.33; P =0.4241) and 1.91 (1.29 -2.83; P =0.0013), respectively (interaction P =0.0038; Figure S1A ).
The second nsSNP that showed consistent pharmacogenomic association in whites and Hispanics was rs893184, located in A1BG ( α -1-B glycoprotein; white interaction P =0.0248, Hispanic interaction P =0.0310, and combined interaction P =0.0036; Table 2 ; Figure  S1B ). rs893184 causes a histidine (His) to arginine (Arg) substitution at amino acid position 52 in A1BG . His carriers had a lower risk for the PO in the CCB strategy in whites and Hispanics, whereas Arg/Arg patients had a higher risk for the PO in the CCB strategy. After pooling the race/ethnic groups, the observed association was stronger (combined interaction P =0.0036; Figure S1B ).
Linkage disequilibrium was assessed between the 2 nsSNPs because they are located 6.85 Mb apart on chromosome 19. Overall, there was very low linkage disequilibrium between them ( r 2 values of 0 and 0.02 in INVEST whites and Hispanics, respectively, and D ′ values of 0.03 and 0.24 in INVEST whites and Hispanics, respectively; Table S3 ).
In addition, gene regions identifi ed from the interaction analysis in whites were investigated in Hispanics. The F5-SELP-SELL-SELE region on chromosome 1 showed strong evidence of association in both whites and Hispanics: multiple nsSNPs associated in each race group. In this region, there were 3 independent nsSNPs with evidence of association in the white race/ethnic group (rs9332701, rs6131, and rs5361; Figure S2 ) and 2 independent nsSNPs with evidence of association in the Hispanic race/ethnic group (rs4525 and rs6125; Figure S3 ). Through linkage disequilibrium assessment and haplotype interaction analysis, we discovered that a 2-SNP haplotype spanning SELP and SELE , rs6125 and rs5361, was associated with treatment interaction in whites and replicated in Hispanics (white interaction P =0.0097, Hispanic interaction P =0.0028, and combined interaction P =0.0003; Table S4 ).
Genetic Risk Score and Replication in NORDIL
We built a genetic risk score in INVEST based on the 2 nsSNPs that showed evidence of association in both INVEST whites and INVEST Hispanics (rs16982743 and rs893184). Results from the treatment interaction analyses with the 2-nsSNP risk score were signifi cant in whites (interaction P =0.0012), Hispanics (interaction P =0.0499), and combined Four of the fi ve 3-SNP models (including the chromosome 19 nsSNPs and then rs9332701, rs4525, rs6131, or rs6125) and the haplotype model showed equal or stronger evidence of association compared with the 2-SNP model (combined interaction P ≤ 0.0004). Next, we sought to replicate the genetic risk score models in NORDIL. Three of the four 3-SNP models above were tested (the model with rs9332701 was not tested because of low rs9332701 minor allele frequency in NORDIL, and the haplotype model was not tested because of the fact that NORDIL data used imputed SNPs, thus construction of haplotypes was not appropriate). These data suggested that rs4525 (His865Arg) in F5 was the most informative nsSNP for the F5 -SELP -SELL -SELE region across studies as part of a 3-SNP model (Table S5 ). The results of the treatment interaction analysis with the 3-SNP model (rs16982743, rs893184, and rs4525) genetic risk score relative to the PO for each of the 3 cohorts are shown in the Figure. We observed consistent associations with the risk score in INVEST whites and Hispanics, with subjects with the low-risk score (0 or 1) being neutral to treatment strategy or trending toward favoring the CCB strategy and subjects with the high-risk score (2 or 3) being at signifi cant risk in the CCB strategy (favoring the β B strategy). In NORDIL, these results replicated, with a signifi cant risk score × treatment interaction (NORDIL interaction P =0.0315, 1-sided P value). When all 3 studies were combined in meta-analysis, the interaction P value was more signifi cant (interaction P =2.39 × 10 − 5 Figure) .
Despite limited power, additional analyses of the risk score on secondary outcomes by genetic risk score in INVEST suggested that each element of the PO contributes ( Figure S4 ). Both nonfatal MI and all-cause death seemed to contribute to the PO pharmacogenomic effect (white/Hispanic combined interaction P =0.0457 and 0.0026, respectively). In addition, nonfatal stroke contributed to the PO pharmacogenomic effect in Hispanics (interaction P =0.0404).
Discussion
We performed a genome-spanning analysis of nsSNPs in cardiovascular, metabolic, and infl ammatory candidate genes to investigate genetic variants associated with differential treatment-related outcomes in high-risk patients with hypertension. Through this analysis, we identifi ed 3 regions with a pharmacogenetic association with treatment-related outcomes in white and Hispanic patients with hypertension and coronary artery disease treated with a CCB versus β B strategy. In 2 of these regions, a single SNP was associated in treatment interaction analysis: SIGLEC12 rs16982743 (Gln29Stop) and A1BG rs893184 (His54Arg). The third region on chromosome 1, containing F5 , SELP, SELL , and SELE , showed evidence of association at multiple SNPs across INVEST whites and Hispanics. A risk score accounting for all 3 regions was signifi cantly associated with treatment outcomes in INVEST whites, INVEST Hispanics, and replicated in NORDIL.
This study represents the fi rst pharmacogenetics study in hypertension to identify and replicate genetic markers for differential treatment-related outcomes across large clinical trials. This was likely aided by selecting SNPs that had associations in independent race/ethnic groups within INVEST for testing in a different clinical trial population. Risk-score pharmacogenomic association with the primary outcome. Risk score calculated from SIGLEC12 rs16982743, A1BG rs893184, and F5 rs4525. One point was given for each genotype that conferred higher risk in the calcium channel blocker (CCB) arm/group vs the β B arm/group: rs16982743 GG (Gln/ Gln), rs893184 GG (Arg/Arg), and rs4525 AA (His/His). Low risk defi ned as a risk score=0 or 1; high risk defi ned as a risk score=2 or 3. # One-sided P value based on 1-sided hypothesis in replication cohort. In addition, the use of a genetic risk score enhanced the ability to replicate the fi nding in NORDIL. Risk scores have been more commonly used in disease genetics, 10 , 11 but their use in pharmacogenomics is valuable for future clinical translation. This is especially true for hypertension pharmacogenomics because often multiple signals are likely involved, as demonstrated in this study. Risk scores are typically constructed from prior association signals and tested in an independent population. 10 , 11 In this study, we constructed the score in the discovery population, but we have replicated the score in an independent population. SIGLEC12 , located at 19q13.4, encodes the sialic acidbinding Ig-like lectin 12 gene. Siglecs are a family of single-pass, type I transmembrane proteins belonging to the immunoglobulin superfamily. Most siglecs are expressed on cells of the immune system or the hematopoietic system.
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SIGLEC12 is expressed on the epithelial cell surface and on some macrophages. 12 It has been suggested that SIGLEC12 could be involved in the negative regulation of macrophage signaling by functioning as an inhibitory receptor. 13 In addition, other members of the siglec family have been shown to be expressed abundantly on macrophages recruited during the pathogenesis of atherosclerosis.
14 Although there are no published data on the function of the Gln29Stop SNP, premature stop codons are essentially always functional, and one this early in the protein would particularly be expected to be functional.
The α -1-B glycoprotein precursor ( A1BG ) is also located at 19q13.4 (6.85 Mb away from SIGLEC12 ) and encodes a plasma glycoprotein with unknown function. The A1BG protein is a member of the immunoglobulin superfamily and has been shown to form a complex with cysteine-rich secretory protein 3, a protein present in neutrophilic granulocytes that is thought to play a role in innate immunity. 15 The last region identifi ed from the treatment interaction analyses contained signals in 3 genes: F5 , coagulation factor V; SELP , selectin P; and SELE , selectin E. Because we did not have a consistent signal across all 3 populations, it is likely we have not found the causal variant in this region. However, we did observe an association or trend in each group, and overall, rs4525 in F5 was the best representation of the signal. All 3 of these genes are located on chromosome 1q22-q25 and span ≈ 220 kb, with SELL (selectin L) located between SELP and SELE . F5 encodes an essential cofactor in the blood coagulation cascade, participating as half of the complex that activates prothrombin to thrombin during the blood clotting process. 16 SELP and SELE are members of the selectin family of cell adhesion molecules and both mediate leukocyte rolling, a process essential for the initiation of atherosclerosis.
17 P-selectin is stored in platelets and endothelial cells and on activation redistributes to the plasma membrane, whereas E-selectin is only expressed on endothelial cells. 17 Prior genetic associations have been seen with F5 , SELP , and SELE and cardiovascular disease. SNPs in F5 have been previously associated with diastolic BP 18 and cardiovascular disease 19 and have shown a signifi cant interaction with pravastatin in relation to cardiovascular events. 20 Association studies have found that variants in SELP are associated with soluble and cell surface measures of P-selectin, 21 coronary heart disease, 21 and MI. 22 Finally, variants in SELE have been associated with BP, 23 essential hypertension, 24 coronary artery disease, 25 stroke, 26 and coronary heart disease in chlorthalidone (diuretic)-treated patients from the GenHAT study. 27 It is noteworthy that all 3 regions identifi ed from a genome-spanning interrogation of nsSNPs are related to immune cell traffi cking or are in the immunoglobulin superfamily. The functions of F5, P-selectin, and E-selectin have been well characterized and variants in all 3 genes have been previously associated with cardiovascular disease. Our data suggest that this region is also associated with treatmentrelated cardiovascular outcomes in patients with hypertension. In addition, we observed evidence of an association with treatment-related cardiovascular outcomes with variants in A1BG and SIGLEC12 . Although the exact functions of these genes are unknown, our results may hint that their functions are also related to the progression of the atherosclerotic environment in the vasculature. From our results, it is unclear whether the CCB strategy advanced this progression, leading to increased risk in the genotypes identifi ed, or whether the β B strategy reduced this risk. We hypothesize that the latter would seem more plausible because it is more likely that one of the drugs is protective in a given genotype, versus a drug adding risk in a specifi c genotype.
Our study is not without limitations. We did not reach a Bonferroni signifi cance level in our initial treatment interaction analysis of nsSNPs on the HumanCVD Beadchip, and we cannot discount the possibility of reaching these results by chance: with a P < 0.00125 for 1313 nsSNPs analyzed in INVEST whites; we would expect 1.6 signifi cant hits, and we found 2. However, our analysis only focused on nonsynonymous SNPs, giving them a higher probability of being functional variants. In addition, consistent associations in both whites and Hispanics in INVEST reduces the risk of these representing a false positive. Replication of the risk score constructed from these SNPs in NORDIL further reduces the likelihood of this representing a chance fi nding. We also had reduced power in by race analyses. Still, we were able to identify 3 regions with evidence of association, and our genetic risk score constructed from these 3 regions was signifi cant in INVEST whites, INVEST Hispanics, and NORDIL. Finally, we may have missed true signals by the design of our study because one of our replication cohorts had a different racial/ethnic background. Nevertheless, true functional variants should be functional across all populations, and there are numerous examples for this within the pharmacogenomics literature.
Perspectives
There is great interpatient variability in antihypertensive drug response, with only ≈ 50% of patients responding to any 1 drug, to provide a potential approach for identifying which patients would benefi t from a CCB strategy versus a β B strategy with regard to treatment-related adverse cardiovascular outcomes. These results require further investigation to clarify their role in hypertension treatment and to establish the mechanism through which they elicit their effect. However, the specifi c genetic associations and our risk score method provide insight into a potential approach to personalized antihypertensive treatment selection.
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Sources of Funding
• Nonsynonymous SNPs in SIGLEC12 , A1BG , and the selectin region are associated with antihypertensive treatment-related adverse cardiovascular events.
What Is Relevant?
• There is great interpatient variability in adverse outcomes related to antihypertensive treatment. This research identifi es SNPs that may contribute to this variability and may help explain differential outcomes with a given hypertension treatment based on genotype.
Summary
Nonsynonymous SNPs in SIGLEC12 , A1BG , and the selectin region are associated with treatment-related adverse cardiovascular outcomes in patients with hypertension and coronary artery disease. A risk score accounting for the 3 regions provides a potential approach for identifying which patients would benefi t from a calcium channel blocker strategy versus a β B strategy.
